Active, Not Recruiting

Trial ID CA246-0005 | NCT05737706

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

Summary

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA.
Unresectable or metastatic disease.
Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts.
Presence of tumor lesions to be evaluated per RECIST v1.1: 1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease. 2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Adequate organ function.
Age ≥ 18 years

Active brain metastases or carcinomatous meningitis.
Prior treatment with a KRAS G12D inhibitor (Phase 1b & Phase 2 only).
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications.
History of malignant small bowel obstruction.
Cardiac abnormalities.

Additional Information *

Study Arms

Experimental: Phase 1/1B

ASSIGNED INTERVENTION

Study Arms

Experimental: Phase 2

ASSIGNED INTERVENTION